Hypertension and the Use of Statins in Terms of New Studies and Guidelines

Yu.M. Sirenko, A.L. Rekovets




Дисліпідемії: діагностика, профілактика та лікування. Методичні рекомендації Асоціації кардіологів України. — К., 2011.

Настанова та клінічний протокол надання медичної допомоги «Артеріальна гіпертензія». — К., 2012.

Medicine review. Кадиологический альманах. Спецвып. Достижения в диагностике, лечении и профилактике сердечно-сосудистых заболеваний. — 2014. — С. 293.

Amarenco P., Callahan A. 3rd, Campese V.M., Goldstein L.B., Hennerici M.G., Messig M., Sillesen H., Welch K.M., Wilson D.J., Zivin J.A. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial // Stroke. — 2014. — Vol. 45. — P. 2974-2982.

Baigent C., Landray M.J., Reith C., Emberson J., Whee­ler D.C., Tomson C., Wanner C., Krane V., Cass A., Craig J., Neal B., Jiang L., Hooi L.S., Levin A., Agodoa L., Gaziano M., Kasiske B., Walker R., Massy Z.A., Feldt-Rasmussen B., Krairittichai U., Ophascharoensuk V., Fellström B., Holdaas H., Tesar V., Wiecek A., Grobbee D., de Zeeuw D., Grönhagen-Riska C., Dasgupta T., Lewis D., Herrington W., Mafham M., Majoni W., Wallendszus K., Grimm R., Pedersen T., Tobert J., Armitage J., Baxter A., Bray C., Chen Y., Chen Z., Hill M., Knott C., Parish S., Simpson D., Sleight P., Young A., Collins R.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial // Lancet — 2011. — Vol. 25, 377(9784). — P. 2181-2192.

Bangalore S., Fayyad R., Hovingh G.K., Laskey R., Vogt L., DeMicco D.A., Waters D.D.; Treating to New Targets Steering Committee and Investigators. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials // Am. J. Cardiol. — 2014. — Vol. 15. — P. 2018-2020.

Bezerra D.G., Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats // Clin. Sci. (Lond). — 2005. — Vol. 108. — P. 349-355.

Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial // Lancet. — 2004. — Vol. 21-27, № 364(9435). — 685-696.

Drapala A., Sikora M., Ufnal M. Statins, the renin-angiotensin-aldosterone system and hypertension — a tale of another beneficial effect of statins // J. Renin. Angiotensin. Aldosterone Syst. — 2014. — Vol. 15. — P. 250-258.

Golomb B.A., Dimsdale J.E., White H.L., Ritchie J.B., Criqui M.H. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial // Arch. Intern Med. — 2008. — Vol. 14. — P. 721-727.

Grip O., Janciauskiene S., Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes // Inflamm. Res. — 2002. — Vol. 51. — P. 58-62.

Heart Protection Study Collaborative Group, Bulbulia R., Bowman L., Wallendszus K., Parish S., Armitage J., Peto R., Collins R. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial // Lancet. — 2011. — Vol. 10. — P. 2013-2020.

Kassan M., Montero M.J., Sevilla M.A. Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats // Br. J. Pharmacol. — 2009. — Vol. 158. — P. 541-547.

Kawut S.M., Bagiella E., Lederer D.J., Shimbo D., Horn E.M., Roberts K.E., Hill N.S., Barr R.G., Rosenzweig E.B., Post W., Tracy R.P., Palevsky H.I., Hassoun P.M., Girgis R.E.; ­ASA-STAT Study Group Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT// Circulation. — 2011. — Vol. 28. — P. 2985-93.

Krader C.G. American Diabetes Association. Diabetes clinical practice recommendations focus attention on individualization of care // Med. Econ. — 2014. — Vol. 25. — P. 22-24.

Ledingham J.M., Laverty R. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model // Clin. Exp. Pharmacol. Physiol. — 2005. — Vol. 32. — P. 76-85.

Leenen F.H. Actions of circulating angiotensin II and aldosterone in the brain contributing to hypertension // Am. J. Hypertens. — 2014. — Vol. 27. — P. 1024-1032.

Lopez-Jimenez F., Simha V., Thomas R.J., Allison T.G., Basu A., Fernandes R., Hurst R.T., Kopecky S.L., Kullo I.J., Mulvagh S.L., Thompson W.G., Trejo-Gutierrez J.F., Wright R.S. A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps // Mayo. Clin. Proc. — 2014. — Vol. 89. — P. 1257-1278.

Lunder M., Ziberna L., Janić M., Jerin A., Skitek M., Sabović M., Drevenšek G. Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta // Heart Vessels. — 2013. — Vol. 28. — P. 246-254.

Mancia G. The ALLHAT study: contributions, limitations and prospectives // Ital. Heart J. Suppl. — 2003. — Vol. 4 — P. 77-84.

Mancini G.B, Tashakkor A.Y., Baker S., Bergeron J., Fitchett D., Frohlich J., Genest J., Gupta M., Hegele R.A., Ng D.S., Pearson G.J., Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update // Can. J. Cardiol. — 2013. — Vol. 29. — P. 1553-1568.

Mora S., Ridker P.M. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) — can C-reactive protein be used to target statin therapy in primary prevention? // Am. J. Cardiol. — 2006. — Vol. 16(2A). — P. 33A-41A.

Priscilla Y. Hsue, Vera A. Bittner, John Betteridge, Rana Fayyad, Rachel Laskey, Nanette K. Wenger, David D. Waters Impact of Female Sex on Lipid Lowering, Clinical Outcomes, and Adverse Effects in Atorvastatin Trials // Am. Journal of Cardiol. — 2015. — Vol. 115. — P. 447-453.

Rabar S., Harker M., O’Flynn N., Wierzbicki A.S.; Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance // BMJ. — 2014. — Vol. 17. — 349.

Sarnak M.J., Bloom R., Muntner P., Rahman M., Saland J.M., Wilson P.W., Fried L. KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD // Am. J. Kidney Dis. — 2015. — Vol. 65. — P. 354-366.

Sever P.S., Poulter N.R., Dahlöf B., Wedel H., Collins R., Beevers G., Caulfield M., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA) // Diabetes Care. — 2005. — Vol. 28. — P. 1151-1157.

Sim J.S., Dick J.B., Struthers A.D. Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients // J. Renin. Angiotensin. Aldosterone Syst. — 2004. — Vol. 5. — P. 109-113.

Spösito A.C., Mansur A.P., Coelho O.R., Nicolau J.C., Ramires J.A. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril) // Am. J. Cardiol. — 1999. — Vol. 15, 83. — P. 1497-1499, A8.

Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines // J. Am. Coll Cardiol. — 2014. — Vol. 1. — P. 2889-2934.

Task Force Members, Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A., Bugiardini R., Crea F., Cuisset T., Di Mario C., Ferreira J.R., Gersh B.J., Gitt A.K., Hulot J.S., Marx N., Opie L.H., Pfisterer M., Prescott E., Ruschitzka F., Sabaté M., Senior R., Taggart D.P., van der Wall E.E., Vrints C.J.; ESC Committee for Practice Guidelines, Zamorano J.L., Achenbach S., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S.; Document Reviewers, Knuuti J., Valgimigli M., Bueno H., Claeys M.J., Donner-Banzhoff N., Erol C., Frank H., Funck-Brentano C., Gaemperli O., Gonzalez-Juana­tey J.R., Hamilos M., Hasdai D., Husted S., James S.K., Kervinen K., Kolh P., Kristensen S.D., Lancellotti P., Maggioni A.P., Piepoli M.F., Pries A.R., Romeo F., Rydén L., Simoons M.L., Sirnes P.A., Steg P.G., Timmis A., Wijns W., Windecker S., Yildirir A., Zamorano J.L. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology // Eur. Heart J. — 2013. — Vol. 34. — P. 2949-3003.

Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD), Rydйn L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N., Deaton C., Escaned J., Hammes H.P., Huikuri H., Marre M., Marx N., Mellbin L., Ostergren J., Patrono C., Seferovic P., Uva M.S., Taskinen M.R., Tendera M., Tuomilehto J., Valensi P., Zamorano J.L. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD — summary // Diab. Vasc. Dis. Res. — 2014. — Vol. 11. — P. 133-173.

Taylor F., Ward K., Moore T.H., Burke M., Davey Smith G., Casas J.P., Ebrahim S. Statins for the primary prevention of cardiovascular disease // Cochrane Database Syst. Rev. — 2013. — 1. — CD004816.

Tesfamariam B., Frohlich B.H., Gregg R.E. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity // J. Cardiovasc. Pharmacol. — 1999. — Vol. 34. — P. 95-101.

Ufnal M., Drapala A., Sikora M., Szczepanska-Sadowska E. Oral simvastatin reduces the hypertensive response to air-jet stress // Clin. Exp. Pharmacol. Physiol. — 2012. — Vol. 39. — P. 350-356.

Wanner C., Tonelli M.; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient // Kidney Int. — 2014. — Vol. 85. — P. 1303-1309.

Zelvyte I., Dominaitiene R., Crisby M., Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro // Pharmacol. Res. — 2002. — Vol. 45. — P. 147-154.

Williams B., Lacy P.S., Cruickshank J.K., Collier D., Hughes A.D., Stanton A., Thom S., Thurston H.; CAFE and ASCOT Investigators. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Eva-luation-Lipid-Lowering Arm (CAFE-LLA) Study // Circulation. — 2009. — Vol. 6. — P. 53-61.

Wang P., Liu Y., Wang Z., Wang Z., Zhao N., Ye H., Ren L. Effects of rosuvastatin on arterial stiffness in hyperlipidemia patients // Zhonghua Yi Xue Za Zhi. — 2014. — Vol. 19. — P. 2452-2454.

Wang Z.G., Chen B.W., Li N.Q., Cheng Y.M., Dang A.M. Relationships between use of statins and arterial stiffness in normotensive and hypertensive patients with coronary artery disease // Chin. Med. J. (Engl). — 2013. — Vol. 126. — P. 3087-3092.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта